nach oben

Arthritis Research & Therapy

Erschienen in:

01.06.2005 | Review

Aetiology and pathogenesis of reactive arthritis: role of non-antigen-presenting effects of HLA-B27

verfasst von: Sanna Vähämiko, Markus A Penttinen, Kaisa Granfors

Erschienen in: Arthritis Research & Therapy | Ausgabe 4/2005

Einloggen, um Zugang zu erhalten

Abstract

Spondyloarthropathies are inflammatory diseases closely associated with human leukocyte antigen (HLA)-B27 by unknown mechanisms. One of these diseases is reactive arthritis (ReA), which is typically triggered by Gram-negative bacteria, which have lipopolysaccharide as an integral component of their outer membrane. Several findings in vivo and in vitro obtained from patients with ReA and from different model systems suggest that HLA-B27 modulates the interaction between ReA-triggering bacteria and immune cells by a mechanism unrelated to the antigen presentation function of HLA-B27. In this review we piece together a jigsaw puzzle from the new information obtained from the non-antigen-presenting effects of HLA-B27.

Nur mit Berechtigung zugänglich

Brewerton DA, Hart FD, Nicholls A, Caffrey M, James DC, Sturrock RD: Ankylosing spondylitis and HL-A 27. Lancet. 1973, i: 904-907. 10.1016/S0140-6736(73)91360-3.CrossRef

Aho K, Ahvonen P, Lassus A, Sievers K, Tiilikainen A: HL-A 27 in reactive arthritis. A study of Yersinia arthritis and Reiter's disease. Arthritis Rheum. 1974, 17: 521-526.CrossRefPubMed

Schwimmbeck PL, Yu DT, Oldstone MB: Autoantibodies to HLA B27 in the sera of HLA B27 patients with ankylosing spondylitis and Reiter's syndrome. Molecular mimicry with Klebsiella pneumoniae as potential mechanism of autoimmune disease. J Exp Med. 1987, 166: 173-181. 10.1084/jem.166.1.173.CrossRefPubMed

Benjamin R, Parham P: Guilt by association: HLA-B27 and ankylosing spondylitis. Immunol Today. 1990, 11: 137-142. 10.1016/0167-5699(90)90051-A.CrossRefPubMed

Whelan MA, Archer JR: Chemical reactivity of an HLA-B27 thiol group. Eur J Immunol. 1993, 23: 3278-3285.CrossRefPubMed

Bird LA, Peh CA, Kollnberger S, Elliott T, McMichael AJ, Bowness P: Lymphoblastoid cells express HLA-B27 homodimers both intracellularly and at the cell surface following endosomal recycling. Eur J Immunol. 2003, 33: 748-759. 10.1002/eji.200323678.CrossRefPubMed

Scofield RH, Kurien B, Gross T, Warren WL, Harley JB: HLA-B27 binding of peptide from its own sequence and similar peptides from bacteria: implications for spondyloarthropathies. Lancet. 1995, 345: 1542-1544. 10.1016/S0140-6736(95)91089-1.CrossRefPubMed

Ahvonen P, Sievers K, Aho K: Arthritis associated with Yersinia enterocolitica infection. Acta Rheumatol Scand. 1969, 15: 232-253.CrossRefPubMed

Granfors K, Jalkanen S, Lindberg AA, Maki-Ikola O, von Essen R, Lahesmaa-Rantala R, Isomaki H, Saario R, Arnold WJ, Toivanen A: Salmonella lipopolysaccharide in synovial cells from patients with reactive arthritis. Lancet. 1990, 335: 685-688. 10.1016/0140-6736(90)90804-E.CrossRefPubMed

10.

Granfors K, Jalkanen S, von Essen R, Lahesmaa-Rantala R, Isomaki O, Pekkola-Heino K, Merilahti-Palo R, Saario R, Isomaki H, Toivanen A: Yersinia antigens in synovial-fluid cells from patients with reactive arthritis. N Engl J Med. 1989, 320: 216-221.CrossRefPubMed

11.

Gerard HC, Branigan PJ, Schumacher HR, Hudson AP: Synovial Chlamydia trachomatis in patients with reactive arthritis/Reiter's syndrome are viable but show aberrant gene expression. J Rheumatol. 1998, 25: 734-742.PubMed

12.

Khan MA: Update on spondyloarthropathies. Ann Intern Med. 2002, 136: 896-907.CrossRefPubMed

13.

Colmegna I, Cuchacovich R, Espinoza LR: HLA-B27-associated reactive arthritis: pathogenetic and clinical considerations. Clin Microbiol Rev. 2004, 17: 348-369. 10.1128/CMR.17.2.348-369.2004.PubMedCentralCrossRefPubMed

14.

Sieper J, Rudwaleit M, Braun J, van der Heijde D: Diagnosing reactive arthritis: role of clinical setting in the value of serologic and microbiologic assays. Arthritis Rheum. 2002, 46: 319-327. 10.1002/art.504.CrossRefPubMed

15.

Hannu T, Puolakkainen M, Leirisalo-Repo M: Chlamydia pneumoniae as a triggering infection in reactive arthritis. Rheumatology (Oxford). 1999, 38: 411-414.CrossRef

16.

Granfors K, Marker-Hermann E, de Keyser F, Khan MA, Veys EM, Yu DT: The cutting edge of spondylarthropathy research in the millennium. Arthritis Rheum. 2002, 46: 606-613. 10.1002/art.10041.CrossRefPubMed

17.

Colbert RA: The immunobiology of HLA-B27: variations on a theme. Curr Mol Med. 2004, 4: 21-30. 10.2174/1566524043479293.CrossRefPubMed

18.

Penttinen MA, Heiskanen KM, Mohapatra R, DeLay ML, Colbert RA, Sistonen L, Granfors K: Enhanced intracellular replication of Salmonella enteritidis in HLA-B27-expressing human monocytic cells. Dependency on glutamic acid at position 45 in the B pocket of HLA-B27. Arthritis Rheum. 2004, 50: 2255-2263. 10.1002/art.20336.CrossRefPubMed

19.

Penttinen MA, Holmberg CI, Sistonen L, Granfors K: HLA-B27 modulates nuclear factor kappaB activation in human monocytic cells exposed to lipopolysaccharide. Arthritis Rheum. 2002, 46: 2172-2180. 10.1002/art.10557.CrossRefPubMed

20.

Cresswell P, Bangia N, Dick T, Diedrich G: The nature of the MHC class I peptide loading complex. Immunol Rev. 1999, 172: 21-28.CrossRefPubMed

21.

Solheim JC: Class I MHC molecules: assembly and antigen presentation. Immunol Rev. 1999, 172: 11-19.CrossRefPubMed

22.

Dangoria NS, DeLay ML, Kingsbury DJ, Mear JP, Uchanska-Ziegler B, Ziegler A, Colbert RA: HLA-B27 misfolding is associated with aberrant intermolecular disulfide bond formation (dimerization) in the endoplasmic reticulum. J Biol Chem. 2002, 277: 23459-23468. 10.1074/jbc.M110336200.CrossRefPubMed

23.

Mear JP, Schreiber KL, Munz C, Zhu X, Stevanovic S, Ram-mensee HG, Rowland-Jones SL, Colbert RA: Misfolding of HLA-B27 as a result of its B pocket suggests a novel mechanism for its role in susceptibility to spondyloarthropathies. J Immunol. 1999, 163: 6665-6670.PubMed

24.

Antoniou AN, Ford S, Taurog JD, Butcher GW, Powis SJ: Formation of HLA-B27 homodimers and their relationship to assembly kinetics. J Biol Chem. 2004, 279: 8895-8902. 10.1074/jbc.M311757200.CrossRefPubMed

25.

Mori K: Tripartite management of unfolded proteins in the endoplasmic reticulum. Cell. 2000, 101: 451-454. 10.1016/S0092-8674(00)80855-7.CrossRefPubMed

26.

Rutkowski DT, Kaufman RJ: A trip to the ER: coping with stress. Trends Cell Biol. 2004, 14: 20-28. 10.1016/j.tcb.2003.11.001.CrossRefPubMed

27.

Maki-Ikola O, Leirisalo-Repo M, Kantele A, Toivanen P, Granfors K: Salmonella-specific antibodies in reactive arthritis. J Infect Dis. 1991, 164: 1141-1148.CrossRefPubMed

28.

Granfors K, Toivanen A: IgA-anti-Yersinia antibodies in Yersinia triggered reactive arthritis. Ann Rheum Dis. 1986, 45: 561-565.PubMedCentralCrossRefPubMed

29.

Granfors K, Merilahti-Palo R, Luukkainen R, Mottonen T, Lahesmaa R, Probst P, Marker-Hermann E, Toivanen P: Persistence of Yersinia antigens in peripheral blood cells from patients with Yersinia enterocolitica O:3 infection with or without reactive arthritis. Arthritis Rheum. 1998, 41: 855-862. 10.1002/1529-0131(199805)41:5<855::AID-ART12>3.0.CO;2-J.CrossRefPubMed

30.

Penttinen MA, Ekman P, Granfors K: Non-antigen presenting effects of HLA-B27. Curr Mol Med. 2004, 4: 41-49. 10.2174/1566524043479275.CrossRefPubMed

31.

Kapasi K, Inman RD: ME1 epitope of HLA-B27 confers class I-mediated modulation of Gram-negative bacterial invasion. J Immunol. 1994, 153: 833-840.PubMed

32.

Kapasi K, Inman RD: HLA-B27 expression modulates Gram-negative bacterial invasion into transfected L cells. J Immunol. 1992, 148: 3554-3559.PubMed

33.

Saarinen M, Ekman P, Ikeda M, Virtala M, Gronberg A, Yu DT, Arvilommi H, Granfors K: Invasion of Salmonella into human intestinal epithelial cells is modulated by HLA-B27. Rheumatology (Oxford). 2002, 41: 651-657.CrossRef

34.

Huppertz HI, Heesemann J: Invasion and persistence of Salmonella in human fibroblasts positive or negative for endogenous HLA B27. Ann Rheum Dis. 1997, 56: 671-676.PubMedCentralCrossRefPubMed

35.

Ortiz-Alvarez O, Yu DT, Petty RE, Finlay BB: HLA-B27 does not affect invasion of arthritogenic bacteria into human cells. J Rheumatol. 1998, 25: 1765-1771.PubMed

36.

Mastroeni P: Immunity to systemic Salmonella infections. Curr Mol Med. 2002, 2: 393-406. 10.2174/1566524023362492.CrossRefPubMed

37.

Ekman P, Nikkari S, Putto-Laurila A, Toivanen P, Granfors K: Detection of Salmonella infantis in synovial fluid cells of a patient with reactive arthritis. J Rheumatol. 1999, 26: 2485-2488.PubMed

38.

Virtala M, Kirveskari J, Granfors K: HLA-B27 modulates the survival of Salmonella enteritidis in transfected L cells, possibly by impaired nitric oxide production. Infect Immun. 1997, 65: 4236-4242.PubMedCentralPubMed

39.

Huppertz HI, Heesemann J: The influence of HLA B27 and interferon-gamma on the invasion and persistence of Yersinia in primary human fibroblasts. Med Microbiol Immunol (Berl). 1996, 185: 163-170. 10.1007/s004300050027.CrossRef

40.

Young JL, Smith L, Matyszak MK, Gaston JS: HLA-B27 expression does not modulate intracellular Chlamydia trachomatis infection of cell lines. Infect Immun. 2001, 69: 6670-6675. 10.1128/IAI.69.11.6670-6675.2001.PubMedCentralCrossRefPubMed

41.

Granfors K: Host–microbe interaction in reactive arthritis: does HLA-B27 have a direct effect?. J Rheumatol. 1998, 25: 1659-1661.PubMed

42.

Gaston JS, Cox C, Granfors K: Clinical and experimental evidence for persistent Yersinia infection in reactive arthritis. Arthritis Rheum. 1999, 42: 2239-2242. 10.1002/1529-0131(199910)42:10<2239::AID-ANR29>3.0.CO;2-L.CrossRefPubMed

43.

Duncan RL, Hoffman J, Tesh VL, Morrison DC: Immunologic activity of lipopolysaccharides released from macrophages after the uptake of intact E. coli in vitro. J Immunol. 1986, 136: 2924-2929.PubMed

44.

Miyake K: Innate recognition of lipopolysaccharide by Toll-like receptor 4-MD-2. Trends Microbiol. 2004, 12: 186-192. 10.1016/j.tim.2004.02.009.CrossRefPubMed

45.

Maini RN: Current and new antitumor necrosis factor agents in perspective. Arthritis Res Ther. 2004, 6 (Suppl 2): S1-S2. 10.1186/ar994.PubMedCentralCrossRefPubMed

46.

Baeten D, Kruithof E, Van den Bosch F, Demetter P, Van Damme N, Cuvelier C, De Vos M, Mielants H, Veys EM, De Keyser F: Immunomodulatory effects of anti-tumor necrosis factor alpha therapy on synovium in spondylarthropathy: histologic findings in eight patients from an open-label pilot study. Arthritis Rheum. 2001, 44: 186-195. 10.1002/1529-0131(200101)44:1<186::AID-ANR25>3.0.CO;2-B.CrossRefPubMed

47.

De Keyser F, Baeten D, Van den Bosch F, Kruithof E, Mielants H, Veys EM: Infliximab in patients who have spondyloarthropathy: clinical efficacy, safety, and biological immunomodulation. Rheum Dis Clin North Am. 2003, 29: 463-479. 10.1016/S0889-857X(03)00052-8.CrossRefPubMed

48.

McGarry F, Walker R, Sturrock R, Field M: The – 308.1 polymorphism in the promoter region of the tumor necrosis factor gene is associated with ankylosing spondylitis independent of HLA-B27. J Rheumatol. 1999, 26: 1110-1116.PubMed

49.

Repo H, Anttonen K, Kilpinen SK, Palotie A, Salven P, Orpana A, Leirisalo-Repo M: CD14 and TNFα promoter polymorphisms in patients with acute arthritis. Special reference to development of chronic spondyloarthropathy. Scand J Rheumatol. 2002, 31: 355-361. 10.1080/030097402320817086.CrossRefPubMed

50.

Repo H, Jaattela M, Leirisalo-Repo M, Hurme M: Production of tumour necrosis factor and interleukin 1 by monocytes of patients with previous Yersinia arthritis. Clin Exp Immunol. 1988, 72: 410-414.PubMedCentralPubMed

51.

Huhtinen M, Repo H, Laasila K, Jansson SE, Kautiainen H, Karma A, Leirisalo-Repo M: Systemic inflammation and innate immune response in patients with previous anterior uveitis. Br J Ophthalmol. 2002, 86: 412-417. 10.1136/bjo.86.4.412.PubMedCentralCrossRefPubMed

52.

Yin Z, Braun J, Neure L, Wu P, Liu L, Eggens U, Sieper J: Crucial role of interleukin-10/interleukin-12 balance in the regulation of the type 2 T helper cytokine response in reactive arthritis. Arthritis Rheum. 1997, 40: 1788-1797.CrossRefPubMed

53.

Hammer RE, Maika SD, Richardson JA, Tang JP, Taurog JD: Spontaneous inflammatory disease in transgenic rats expressing HLA-B27 and human β₂m: an animal model of HLA-B27-associated human disorders. Cell. 1990, 63: 1099-1112. 10.1016/0092-8674(90)90512-D.CrossRefPubMed

54.

Taurog JD, Richardson JA, Croft JT, Simmons WA, Zhou M, Fernandez-Sueiro JL, Balish E, Hammer RE: The germfree state prevents development of gut and joint inflammatory disease in HLA-B27 transgenic rats. J Exp Med. 1994, 180: 2359-2364. 10.1084/jem.180.6.2359.CrossRefPubMed

55.

Tran TM, Satumtira N, Dorris ML, May E, Wang A, Furuta E, Taurog JD: HLA-B27 in transgenic rats forms disulfide-linked heavy chain oligomers and multimers that bind to the chaperone BiP. J Immunol. 2004, 172: 5110-5119.CrossRefPubMed

56.

Khare SD, Luthra HS, David CS: Spontaneous inflammatory arthritis in HLA-B27 transgenic mice lacking β₂-microglobulin: a model of human spondyloarthropathies. J Exp Med. 1995, 182: 1153-1158. 10.1084/jem.182.4.1153.CrossRefPubMed

57.

Khare SD, Hansen J, Luthra HS, David CS: HLA-B27 heavy chains contribute to spontaneous inflammatory disease in B27/human β₂-microglobulin (β₂m) double transgenic mice with disrupted mouse β₂m. J Clin Invest. 1996, 98: 2746-2755.PubMedCentralCrossRefPubMed

58.

Kingsbury DJ, Mear JP, Witte DP, Taurog JD, Roopenian DC, Colbert RA: Development of spontaneous arthritis in β₂-microglobulin-deficient mice without expression of HLA-B27: association with deficiency of endogenous major histocompatibility complex class I expression. Arthritis Rheum. 2000, 43: 2290-2296. 10.1002/1529-0131(200010)43:10<2290::AID-ANR17>3.0.CO;2-6.CrossRefPubMed

59.

Kollnberger S, Bird LA, Roddis M, Hacquard-Bouder C, Kubagawa H, Bodmer HC, Breban M, McMichael AJ, Bowness P: HLA-B27 heavy chain homodimers are expressed in HLA-B27 transgenic rodent models of spondyloarthritis and are ligands for paired Ig-like receptors. J Immunol. 2004, 173: 1699-1710.CrossRefPubMed

Titel: Aetiology and pathogenesis of reactive arthritis: role of non-antigen-presenting effects of HLA-B27
verfasst von: Sanna Vähämiko
Markus A Penttinen
Kaisa Granfors
Publikationsdatum: 01.06.2005
Verlag: BioMed Central
Erschienen in: Arthritis Research & Therapy / Ausgabe 4/2005
Elektronische ISSN: 1478-6362
DOI: https://doi.org/10.1186/ar1762

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

25.04.2024 | Hypotonie | Nachrichten

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Aetiology and pathogenesis of reactive arthritis: role of non-antigen-presenting effects of HLA-B27

Abstract

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Update Innere Medizin

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2005

Screening of an endothelial cDNA library identifies the C-terminal region of Nedd5 as a novel autoantigen in systemic lupus erythematosus with psychiatric manifestations

Osteoporosis in experimental postmenopausal polyarthritis: the relative contributions of estrogen deficiency and inflammation

Histone deacetylases – a new target for suppression of cartilage degradation?

Early rheumatoid arthritis is characterized by a distinct and transient synovial fluid cytokine profile of T cell and stromal cell origin

The differential contribution of tumour necrosis factor to thermal and mechanical hyperalgesia during chronic inflammation

Regeneration of the immunoglobulin heavy-chain repertoire after transient B-cell depletion with an anti-CD20 antibody

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Update Innere Medizin